Actualización en el abordaje de cefaleas

Bibliografía

1. Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007;27(5):394-402.
2. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. Headache. 2015; 55 (1): 3-20.
3. Tfelt-Hansen P, Rolan P. Nonsteroidal anti-inflammatory drugs in the acute treatment of migraines. En: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, editors. The headaches, 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2006; 449-58.
4. Huerta M, Beltrán I, González C, Jurado C, Latorre G, Pascual J. Migraña Episódica. En Ezpeleta D, Pozo Rosich P, Viguera Romero J, Gago Veiga A, Santos Lasaosa S. Guía Oficial de práctica clínica en cefaleas. Ediciones Luzán S.A., Madrid, 2015.
5. Ferrari MD, Roon KI, Lipton RB, Goadsby PG. Oral triptans (serotonin 5- HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001; 358: 1688-75.
6. Ferrari MD, Goadsby PG, Roon KI, Lipton RB. Triptans (serotonin 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002; 22: 633-58.
7. Pascual J, Mateos V, Roig C, Sanchez-Del-Rio M, Jiménez D. Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability. Headache. 2007; 47: 1152-68.
8. Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004; 44: 414-25
9. Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs. 2010; 70: 1505-18
10. Weatherall MW. Drug therapy in headache. Clinical Medicine. 2015; 15(3): 273–9.
11. Ficha técnica de Zomig 5 mg para pulverización nasal, extraída de: https://cima.aemps.es/cima/dochtml/ft/65163/FichaTecnica_65163.html
12. Pozo Rosich P, Castrillo Sanz A, Fabregat Fabra M, Gago Veiga A, Torres Ferrús M. Esquema Terapéutico en urgencias de las cefaleas primarias y neuralgias. En Guía Práctica diagnóstico terapéutica de la Cefalea del adulto y el niño en Urgencias. Ediciones Luzán S. A., Madrid, 2016.
13. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane database Syst Rev 2017; 2: CD003225.
14. Limmroth V, Biondi D, Pfeil J, Schwalen S. Topiramate in patients with episodic migraine: Reducing the risk for chronic forms of headache. Headache. 2007; 47: 13-21.
15. Pascual-Gómez J, Gracia-Naya M, Leira R, Mateos V, Alvaro-González LC, Hernando I, et al. Zonisamida en el tratamiento preventivo de la migraña refractaria. Rev Neurol (Barc). 2010; 50: 129-32.
16. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997; 17: 103-108.
17. Couch JR. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011; 51: 33-51.
18. Ozyalcin SN, Talu GK, Kizitan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005; 45:144-52.
19. Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014; 34: 523-32.
20. Gales BJ, Bailey EK, Reed AN, Gales MA. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Ann Pharmacother. 2010; 44: 360-6.
21. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: A randomized trial. Headache. 2004; 44: 885-890.
22. Alstadhaug KB, Odeh F, Salvesen R, Bekkelund SI. Prophylaxis of migraine with melatonin: A randomized controlled trial. Neurology. 2010; 75: 1527-32.
23. Guerrero AL, García Azorín D. Tratamiento preventivo de la migraña. En Actualización en las opciones terapéuticas en cefalea 2017. Ediciones Luzán S. A., Madrid, 2017.
24. Guerrero AL, Díaz S, López L, Oterino A, Irimia P. Migraña Crónica. En Ezpeleta D, Pozo Rosich P, Viguera Romero J, Gago Veiga A, Santos Lasaosa S. Guía Oficial de práctica clínica en cefaleas. Madrid: Ediciones Luzán S.A.; 2015.
25. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache. 2008; 48: 1157-68.
26. Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache. 2008;48:7-15.
27. Stovner LJ, Linde M, Gravdahl Gb, Tronvik E, Aamodt AH, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, doublé cross-over study. Cephalalgia. 2013;34:523-32.
28. Diener H, Bussone G, Van Oene JC, Lahaye M, Schwalen S, et al. TOPMAT-MIG-201 (TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814-23.
29. Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, et al. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain. 2008;9:37-41.
30. Pascual-Gómez J, Gracia-Naya M, Leira R, Valentín M, Álvaro-González IH, et al. Zonisamide in the preventive treatment of refractory migraine. Rev Neurol. 2010;50:129-32.
31. Gracia-Naya M, Ríos C, García-Gomara MJ, Sánchez.Valiente S, Mauri-llerda JA, et al. A comparative study of the effectiveness of topiramate and flunarizine in independent series of chronic migraine patients without medication abuse. Rev Neurol (Barc). 2013;57:347-53.
32. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010; 30: 793-803.
33. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30: 804-14.
34. Aurora SK, Winner P, Freeman MC, Turkel CC, DeGryse Re, et al. OnabotulinumtoxinA form treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011; 51: 1358-73.
35. Inan LE, Inan N, Karadas Ö, Gül HL, Erdemoglu Ak, et all. Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study. Acta Neurol Scand. 2015;32:270-7.
36. Porta-Etessam J, Cuadrado Pérez ML, Esteve Belloch P, Hervás García M. Cefalea tipo tensión. En Ezpeleta D, Pozo Rosich P, Viguera Romero J, Gago Veiga A, Santos Lasaosa S. Guía Oficial de práctica clínica en cefaleas. Ediciones Luzán S.A., Madrid, 2015.
37. Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010; 341:c5222.
38. Bendsten L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology. 2004; 62:1706-11.
39. Law S, Derry S, Moore RA. Triptans for acute cluster headache. Cochrane Database Syst Rev. 2013; 17 (7): CD008042.
40. Cohen AS, Burns B; Goadsby PJ. High-Flow Oxygen for Treatment of Cluster HeadacheA Randomized Trial. JAMA. 2009; 302(22): 2451-7.
41. Pareja JA, Caminero AB, Iniesta JA, Ordá CS, Santos Lasaosa S. Cefaleas Trigémino-Autonómicas. Guía Oficial de práctica clínica en cefaleas 2015. Grupo de Estudio de Cefaleas de la SEN. pp. 131-48.
42. Stochino ME, Deidda A, Asuni C, Cherchi A, Manchia M, Del Zompo M. Evaluation of Lithium Response in Episodic Cluster Headache: A Retrospective Case Series. Headache. 2012 Jul-Aug;52(7):1171-5.
43. D’Andrea G, Granella F, Ghiotto N, Nappi G. Lamotrigine in the treatment of SUNCT syndrome. Neurology. 2001; 57: 1723–5.